Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Other Accumulated Expenses: 2022-2025

Historic Other Accumulated Expenses for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Sep 2025 value amounting to $1.7 million.

  • Orchestra BioMed Holdings' Other Accumulated Expenses rose 43.88% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 43.88%. This contributed to the annual value of $579,000 for FY2024, which is 46.34% down from last year.
  • According to the latest figures from Q3 2025, Orchestra BioMed Holdings' Other Accumulated Expenses is $1.7 million, which was up 92.49% from $879,000 recorded in Q2 2025.
  • In the past 5 years, Orchestra BioMed Holdings' Other Accumulated Expenses ranged from a high of $1.9 million in Q4 2022 and a low of $379,000 during Q2 2024.
  • In the last 3 years, Orchestra BioMed Holdings' Other Accumulated Expenses had a median value of $1.0 million in 2024 and averaged $1.0 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first plummeted by 61.21% in 2024, then soared by 131.93% in 2025.
  • Orchestra BioMed Holdings' Other Accumulated Expenses (Quarterly) stood at $1.9 million in 2022, then crashed by 43.00% to $1.1 million in 2023, then tumbled by 46.34% to $579,000 in 2024, then skyrocketed by 43.88% to $1.7 million in 2025.
  • Its Other Accumulated Expenses was $1.7 million in Q3 2025, compared to $879,000 in Q2 2025 and $1.1 million in Q1 2025.